More recently, an NLRP3 selective inhibitor improved NAFLD pathology either in the appetite-defective foz/foz mice overnutrition model fed an atherogenic diet or in the MCD model25. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.